News
The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...
AstraZeneca PLC (NASDAQ:AZN) is included among the Top 10 Safest Dividend Stocks in the UK. AstraZeneca PLC (NASDAQ:AZN) is ...
AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...
The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...
The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...
The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...
Explore more
UK-based pharmaceutical giant AstraZeneca plans to build its largest drug manufacturing facility in Virginia, creating ...
This week's episode covers news about Sarepta, babies born following mitochondrial transfer, and AI identifying therapy targets.
Ahead of the 10-year anniversary of Tagrisso’s initial FDA approval this fall, AstraZeneca has debuted the first ...
British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...
AstraZeneca's strategic $50B investment promises to revolutionize U.S. medicine production with advanced manufacturing and ...
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results